NeoGenomics (NASDAQ:NEO) Stock Price Up 9.4%

   2022-06-25 10:06


NeoGenomics, Inc. (NASDAQ:NEO – Get Rating)’s stock price rose 9.4% on Thursday . The stock traded as high as $8.68 and last traded at $8.65. Approximately 44,184 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 1,670,980 shares. The stock had previously closed at $7.91.



NEO has been the topic of several research reports. Needham & Company LLC decreased their price target on shares of NeoGenomics from $29.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. SVB Leerink reduced their target price on shares of NeoGenomics from $45.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 29th. Benchmark reduced their target price on shares of NeoGenomics from $26.00 to $16.00 in a research note on Tuesday, March 29th. Bank of America downgraded shares of NeoGenomics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $25.00 to $18.00 in a research note on Tuesday, March 29th. Finally, Cowen reduced their target price on shares of NeoGenomics from $42.00 to $24.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.82.


The company has a quick ratio of 7.64, a current ratio of 7.93 and a debt-to-equity ratio of 0.50. The business’s fifty day moving average is $8.99 and its two-hundred day moving average is $17.89.

NeoGenomics (NASDAQ:NEO – Get Rating) last announced its quarterly earnings data on Wednesday, April 27th. The medical research company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The business had revenue of $117.17 million during the quarter, compared to analyst estimates of $116.44 million. NeoGenomics had a negative net margin of 7.33% and a negative return on equity of 6.62%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) EPS. Research analysts expect that NeoGenomics, Inc. will post -1.03 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Captrust Financial Advisors grew its holdings in NeoGenomics by 404.7% during the 1st quarter. Captrust Financial Advisors now owns 4,936 shares of the medical research company’s stock worth $60,000 after acquiring an additional 3,958 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of NeoGenomics by 56.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,826 shares of the medical research company’s stock worth $62,000 after buying an additional 662 shares during the last quarter. Lindbrook Capital LLC purchased a new stake in shares of NeoGenomics during the 4th quarter worth approximately $84,000. Andrew Hill Investment Advisors Inc. purchased a new stake in shares of NeoGenomics during the 4th quarter worth approximately $88,000. Finally, Calton & Associates Inc. purchased a new stake in shares of NeoGenomics during the 1st quarter worth approximately $125,000. Institutional investors own 95.03% of the company’s stock.

NeoGenomics Company Profile (NASDAQ:NEO)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

Recommended Stories



Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.





Original Source